Benitec Biopharma Inc.

Benitec Biopharma Inc. (Nasdaq Capital Market: BNTC) is a clinical-stage biotechnology company headquartered in Hayward, California and focused on developing novel genetic medicines. The company's website is www.benitec.com.

The company's core business centers on advancing BB-301, an investigational gene therapy designed to treat Oculopharyngeal Muscular Dystrophy (OPMD), a rare, chronic, life-threatening genetic disorder characterized by progressive swallowing difficulties, eyelid drooping, and limb weakness. BB-301 represents Benitec's lead product candidate and employs the company's proprietary "silence and replace" therapeutic approach combined with its DNA-directed RNA interference (ddRNAi) technology platform.

BB-301 utilizes a modified adeno-associated virus serotype 9 vector to deliver genetic constructs that simultaneously silence the disease-causing mutant PABPN1 gene through short hairpin RNA molecules while replacing it with a functional gene variant. This dual mechanism aims to provide a permanent therapeutic solution following a single administration, addressing key limitations of traditional RNA interference approaches that require repeat dosing and carry compliance challenges.

The Investigational New Drug application for BB-301 received FDA approval in June 2023, with the first patient dosed in the Phase 1b/2a clinical trial in November 2023. BB-301 has received Orphan Drug Designation and Fast Track Designation in the United States and Orphan Drug Designation in the European Union. The company estimates the commercial opportunity for an effective OPMD therapeutic exceeds one billion dollars over the product's commercial life.

Benitec's intellectual property portfolio includes five active patent families covering the shRNA and shmiR molecules targeting PABPN1, the silence and replace construct, treatment strategies, proprietary AAV vectors with modified phospholipase domains, proprietary injection needles for delivery, and intraoperative administration methods. The company does not operate manufacturing facilities and relies on contract manufacturing organizations operating under current good manufacturing practice standards. Benitec has not yet established sales and marketing operations, planning instead to pursue strategic alliances and distribution agreements for any approved products.